Pharmacogenetics of thiopurines: Can posology be guided by laboratory data?

Radiology and Oncology

Volumn 38, Issue 2, 2004, Pages

  Stocco, Gabriele ^a   Martelossi, Stefano ^b   Decorti, Giuliana ^a   Ventura, Alessando ^b   Malusà, Noelia ^c   Bartoli, Fiora ^a   Giraldi, Tullio ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^c Sanitary Services Agency Number 1   (Italy)

Author keywords

6 mercaptopurine; Azathioprine; Genotype; Inflammatory bowel diseases drug therapy; Phenotype

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; AZATHIOPRINE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CROHN DISEASE; ENTERITIS; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GENE; GENE MUTATION; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; NAUSEA; NUCLEOTIDE SEQUENCE; PANCREATITIS; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TMPT GENE; TOXIC HEPATITIS; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 3142724744     PISSN: 13182099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 329-39.
2. Elion GB. The purine path to chemotherapy. Science 1989; 244: 41-7.
3. Krynetski EY, Krynetskaia NF, Gallo AE, Murti KG, Evans WE. A novel protein complex distinct from mismatch repair binds thioguanylated DNA. Mol Pharmacol 2001; 59: 367-74.
4. Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine and azathioprine. J Clin Oncol 2001; 19: 2293-301.
5. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91: 2001-8.
6. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129: 716-8.
7. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukaemia. Leukemia 2000; 14: 567-72.
8. Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanism and clinical importance. Pharmacology 2000; 61: 136-46.
9. Weinshilboum RM, Otterness DM, Szumlanski CI. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase and histamine N-methyltransferase. Ann Rev Pharmacol Toxicol 1999; 39: 19-52.
10. Krynetski E, Evans WE. Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 2003; 20: 7403-13.
11. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukaemia. J Pediatr 1991; 119: 985-9.
12. Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, Kun LE et al. High incidence of secondary brain tumors after radiotherapy and antimetabolites. Lancet 1999; 354: 34-9.
13. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med. 1997; 126: 608-14.
14. Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999; 8: 371-6.
15. Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 1743-50.
16. Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyl transferase polymorphism. Pharmacogenetics 2002; 12: 429-36.
17. Taylor E, Matsutani M, Barry M, Bogdart R, Wassman ER. TPMT genotype-phenotype accuracy in IBD patients (Abstract). Gastroenterology 2002; 122: S1045.
18. Marshall E. Preventing toxicity with a gene test. Science 2003; 302: 588-90.
19. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med 1995; 123: 132-42.
20. Lamers CB, Griffioen G, van Hogezand RA, Veenendaal RA. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol Suppl 1999; 230: 111-5.
21. George J, Present JH, Pou R. The long-term outcome of ulcerative colitis treated with mercaptopurine. Am J Gastroenterol 1996; 1991: 1711-4.
22. Anglicheau D, Sanquer S, Loriot MA, Beaune P, Thervet E. Thiopurine methyltransferase activity: new conditions for reversed-phase high-performance liquid chromatographic assay without extraction and genotypic-phenotypic correlation. J Chromatogr B 2002; 773: 119-27.
23. Masahiro H, Tomoko I, Omori F, Agatsuma Y, Mizugaki M. Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population. Mutation Res 2000; 448: 91-5.
24. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, et al. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphism. Clin Pharm Ther 1997; 62: 60-73.
25. Rossi AM, Bianchi M, Guarnirei C, Barale R, Pacifici GM. Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects. Eur J Clin Pharmacol 2001; 57: 51-4.
26. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF, Evans WE. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet. 1996; 58: 694-702.
27. Colombel JF, Ferrari N, Debuysere H, Marteau P, Genere JP, Bonaz B, et al. Genotypic Analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30.
28. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA, Robert RL, Kennedy MA. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 395-400.
29. Gardiner SJ, Begg EJ, Barclay ML, Kirkpatrick CMJ. Genetic polymorphism and outcomes with azathioprine and mercaptopurine. Adverse Drug React Toxicol Rev 2000; 19: 293-312.
30. Lewis LD, Benin A, Szumlanski CL, Otterness DM, Lennard L, Weinshilbourn RM, Nierenberg DW. Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction. Clin Pharm Ther 1997; 67: 464-75.
31. Dewit O, Vanheuverzwyn R, Desager JP, Horsman Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002; 16: 79-85.
32. Choi KH, Chen CJ, Kriegler M, Robinson IB. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (p-glycoprotein) gene. Cell 1988; 53: 519-29.
33. Lee AU, Farrell GC. Mechanism of azathioprine-induced injury to hepatocytes: roles of glutathione depletion and mitochondrial injury. J Hepatol 2001; 35: 756-64.
34. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1: 133-43.
35. Check MH, Yang W, Pui CH, Downing JR, Cheng C, Naeve CW, Relling MV, Evans WE. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet. 2003; 34: 85-90.
36. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 1133-45.